Omeprazole Olikla (Omeprazole)

Omeprazole Olikla is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for:

• Gastro‑oesophageal reflux disease (GERD): relief of heartburn and erosion healing.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production.
• Eradication regimens for Helicobacter pylori: enhances antibiotic effectiveness by reducing acid.
• NSAID‑associated ulcer prophylaxis: lowers risk of ulcer development in chronic NSAID users.

• Omeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Adverse reactions to Omeprazole Olikla are generally mild to moderate and vary with individual sensitivity.

Common Side Effects

• Headache: mild, transient headache.
• Diarrhea: loose stools, often self‑limiting.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased gas production.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhea.
• Low magnesium levels: muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: abnormal liver function tests.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When using Omeprazole Olikla, consider the following safety measures:

• Assess renal function: adjust use in patients with severe kidney impairment.
• Review hepatic status: use cautiously in moderate to severe liver disease.
• Monitor long‑term therapy: evaluate need for continued treatment after 12 months.
• Check for drug interactions: assess concomitant medications that may alter acid levels.
• Pregnancy and lactation: weigh benefits against potential risks; consult a healthcare professional.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole Olikla can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir: markedly decreased antiviral exposure, compromising HIV therapy.
• Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring more frequent monitoring.
• Digoxin: slight increase in serum levels, may need dose adjustment.
• Diazepam: enhanced sedation, monitor for excessive drowsiness.